SRF has launched a fundraising campaign on experiment.com to fund projects in damage repair research. Find out more about our Research Department’s amazing projects, and be a part of our quest by donating today.
When blood from a biologically aged animal is transfused into a young one, the young animal suffers “pro-aging” effects. By contrast, reducing the burden of “pro-aging” signaling factors in old blood is not enough to remove existing damage from a similar-aged mouse’s biologically aged tissues.
UNITY Biotechnology was the first senolytic startup out of the gate, and the failure of its Phase II trial in osteoarthritis was a crushing disappointment. A careful look back at the underlying science and three new scientific papers give us a good idea why and suggest ways to move forward.
One way senescent cells accumulate is when one senescent cell turns a neighboring cell senescent through SASP secretion. SRF scientists have discovered that these secondary senescent cells are resistant to the classic senolytic drugs. However, they have identified a new senolytic strategy that kills these senescent cells.
Week One of our 2022 End of Year Campaign features ApoptoSENS (Removing Dysfunctional Cells) – with a disease focus on Challenging Alzheimer’s. Also featuring videos from Life Noggin, AMA with Dr. Amit Sharma and Michael Rae.
A supporter asks if SENS rejuvenation biotechnologies will benefit patients with progerias — so-called “premature aging” diseases.
For our SENSible Question series, a supporter asks if there are any common lab tests available that could be used as a readout of a person’s burden of inflammatory signals from senescent cells. The answer is ‘no,’ unfortunately, but we review a number of hard-to-access or research-only tests that might be able to tell us something with a bit more work.
Sign up to stay informed about the latest news and opportunities with SRF!
Use of this Web site constitutes acceptance of the Terms of Use and Privacy Policy.
© 2023 SENS Research Foundation – ALL RIGHTS RESERVED
